GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » Cyclically Adjusted FCF per Share

Xvivo Perfusion AB (Xvivo Perfusion AB) Cyclically Adjusted FCF per Share : $0.06 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Xvivo Perfusion AB's adjusted free cash flow per share for the three months ended in Mar. 2024 was $0.005. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.06 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Xvivo Perfusion AB's average Cyclically Adjusted FCF Growth Rate was 36.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-08), Xvivo Perfusion AB's current stock price is $43.09. Xvivo Perfusion AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.06. Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF of today is 718.17.

During the past 12 years, the highest Cyclically Adjusted Price-to-FCF of Xvivo Perfusion AB was 656.72. The lowest was 291.30. And the median was 452.35.


Xvivo Perfusion AB Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Xvivo Perfusion AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Cyclically Adjusted FCF per Share Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.06 0.04

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.06 0.04 0.06

Competitive Comparison of Xvivo Perfusion AB's Cyclically Adjusted FCF per Share

For the Medical Devices subindustry, Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF falls into.



Xvivo Perfusion AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xvivo Perfusion AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.005/132.2054*132.2054
=0.005

Current CPI (Mar. 2024) = 132.2054.

Xvivo Perfusion AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.006 100.432 0.008
201409 0.028 100.161 0.037
201412 -0.038 100.225 -0.050
201503 -0.032 99.950 -0.042
201506 0.049 99.995 0.065
201509 0.016 100.228 0.021
201512 0.016 100.276 0.021
201603 0.030 100.751 0.039
201606 0.045 101.019 0.059
201609 0.026 101.138 0.034
201612 -0.029 102.022 -0.038
201703 -0.010 102.022 -0.013
201706 0.030 102.752 0.039
201709 0.036 103.279 0.046
201712 0.036 103.793 0.046
201803 0.042 103.962 0.053
201806 0.096 104.875 0.121
201809 0.016 105.679 0.020
201812 -0.010 105.912 -0.012
201903 0.001 105.886 0.001
201906 0.083 106.742 0.103
201909 0.060 107.214 0.074
201912 -0.029 107.766 -0.036
202003 0.035 106.563 0.043
202006 0.010 107.498 0.012
202009 -0.007 107.635 -0.009
202012 -0.091 108.296 -0.111
202103 0.041 108.360 0.050
202106 -0.055 108.928 -0.067
202109 -0.034 110.338 -0.041
202112 -0.002 112.486 -0.002
202203 -0.033 114.825 -0.038
202206 -0.005 118.384 -0.006
202209 0.053 122.296 0.057
202212 0.071 126.365 0.074
202303 -0.040 127.042 -0.042
202306 0.049 129.407 0.050
202309 0.074 130.224 0.075
202312 0.059 131.912 0.059
202403 0.005 132.205 0.005

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Xvivo Perfusion AB  (OTCPK:XVIPF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Xvivo Perfusion AB's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=43.09/0.06
=718.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted Price-to-FCF of Xvivo Perfusion AB was 656.72. The lowest was 291.30. And the median was 452.35.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Xvivo Perfusion AB Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (Xvivo Perfusion AB) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.